RxDoctor Payments Data

Charles Wade, MD

Cardiovascular Disease · Portsmouth, VANPI 1184820003

Payments from drug & device makers

$1,830in general payments, 2019–2025

Across 96 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$302
  • E.r. Squibb & Sons, L.L.C.$302
  • Novartis$232
  • Novo Nordisk$211
  • Boehringer Ingelheim$171
  • Abbott$148
  • plus $464 from 12 others

What the payments were for

  • Food & beverage$1,79898%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,830 in reported general payments places this provider in the 50th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$422,690
Medicare patients
1,910
Services billed
4,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$206,183
XareltoRivaroxaban81$81,021
FarxigaDapagliflozin Propanediol48$51,663
JardianceEmpagliflozin36$48,106
WegovySemaglutide19$35,626
Repatha SureclickEvolocumab13$21,489
Praluent PenAlirocumab15$9,298
Carvedilol ErCarvedilol Phosphate19$8,760
Rosuvastatin Calcium489$7,560
Metoprolol Succinate408$7,496
Valsartan144$6,613
Atorvastatin Calcium235$2,489
Nifedipine ErNifedipine57$2,288
Losartan Potassium140$1,984
Torsemide98$1,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$206,183170 claims
Johnson & JohnsonXarelto$84$81,02181 claims
AstraZenecaFarxiga$113$51,66348 claims
Boehringer IngelheimJardiance$171$48,10636 claims
Novo NordiskWegovy$211$35,62619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Portsmouth

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →